← Patent-cliff monitor small molecule LINZESS LINACLOTIDE
Loss of exclusivity February 2034 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name LINZESS Active ingredient LINACLOTIDE Strength 72MCG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval January 2017 Marketing status RX
Listed patents Patent Expires Type 9708371*PED February 2034 — 9708371 August 2033 product 10702576*PED February 2032 — 10675325*PED February 2032 — 8933030*PED August 2031 — 10702576 August 2031 use U-4566 10675325 August 2031 product 8933030 February 2031 product 7304036*PED February 2027 — 7304036 August 2026 substance, product
Regulatory exclusivity Code Expires NPP May 2029 I-921 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.